Table 2.
Factors contributing to overall survival by univariate and multivariate analysis
| MST | p value | HR | 95% CI | |
|---|---|---|---|---|
| Univariate analysis | ||||
| Initial treatment | 0.009 | 2.427 | 1.217–4.838 | |
| Sorafenib | 120 | |||
| LFP | 309 | |||
| Performance status | 0.007 | 0.426 | 0.224–0.809 | |
| 0 | 412 | |||
| 1 | 198 | |||
| Age | 0.751 | 0.904 | 0.483–1.691 | |
| <70 years | 268 | |||
| ≥70 years | 217 | |||
| Sex | 0.072 | 2.923 | 0.865–9.870 | |
| Male | 221 | |||
| Female | 224 | |||
| Child-Pugh score | 0.001 | 0.311 | 0.154–0.631 | |
| 5 | 430 | |||
| 6 | 152 | |||
| Vp | 0.270 | 0.700 | 0.370–1.325 | |
| 3 | 308 | |||
| 4 | 120 | |||
| Extrahepatic spread | 0.001 | 0.292 | 0.135–0.633 | |
| Negative | 326 | |||
| Positive | 117 | |||
| Main tumor size | 0.014 | 0.441 | 0.225–0.864 | |
| ≥66.5 mm | 430 | |||
| >66.5 mm | 206 | |||
| Tumor burden | 0.059 | 0.542 | 0.284–1.033 | |
| ≤50% | 309 | |||
| >50% | 200 | |||
| TACE history | 0.448 | 1.275 | 0.679–2.394 | |
| Negative | 240 | |||
| Positive | 221 | |||
| Hepatitis B virus | 0.515 | 0.806 | 0.420–1.546 | |
| Positive | 240 | |||
| Negative | 217 | |||
| Hepatitis C virus | 0.905 | 0.961 | 0.496–1.860 | |
| Positive | 221 | |||
| Negative | 240 | |||
| Non-B non-C | 0.460 | 0.778 | 0.400–1.517 | |
| Positive | 206 | |||
| Negative | 224 | |||
| Alpha-fetoprotein | 0.617 | 0.855 | 0.461–1.585 | |
| ≤466.1 ng/mL | 318 | |||
| >466.1 ng/mL | 198 | |||
| PIVKA-II | 0.010 | 0.425 | 0.217–0.829 | |
| ≤5,080 mAU/mL | 412 | |||
| >5,080 mAU/mL | 206 | |||
| Multivariate analysis | ||||
| Initial treatment | 0.005 | |||
| Sorafenib | ||||
| LFP | 0.249 | 0.095–0.665 | ||
| Performance status | 0.017 | |||
| 0 | ||||
| 1 | 2.660 | 1.188–5.957 | ||
| Sex | 0.356 | |||
| Male | ||||
| Female | 0.498 | 0.113–2.187 | ||
| Child-Pugh score | <0.001 | |||
| 5 | ||||
| 6 | 4.204 | 1.903–9.288 | ||
| Extrahepatic spread | 0.059 | |||
| Negative | ||||
| Positive | 2.392 | 0.969–5.906 | ||
| Main tumor size | 0.537 | |||
| ≤66.5 mm | ||||
| >66.5 mm | 1.342 | 0.528–3.412 | ||
| Tumor burden | 0.046 | |||
| ≤50% | ||||
| >50% | 2.530 | 1.015–6.309 | ||
| PIVKA-II | 0.232 | |||
| ≤5,080 mAU/mL | ||||
| >5,080 mAU/mL | 0.568 | 0.225–1.435 | ||
CI, confidence interval; HR, hazard ratio; LFP, low-dose 5-fluorouracil and cisplatin; MST, median survival time; PIVKA-II, protein induced by vitamin K absence or antagonist II; TACE, transarterial chemoembolization; Vp, tumor thrombus involving the portal vein.